SIGA Technologies

SIGA Technologies is a commercial-stage health security company focused on the treatment of smallpox and other orthopoxviruses. It has contracts with both the US and Canadian governments for TPOXX, its treatment for smallpox, and is expanding internationally.

Equities

Equities by Sector

Sectors

Thematics

Latest

Molten Ventures – Disciplined management and a diversified portfolio

Q325 reflections: Europe’s moment

Molten Ventures is looking to invest in tech companies that see new ways for the world to work

Audiovisual

Latest

Herantis Pharma – executive interview

Take on Trusts – October 2025

Finsbury Growth & Income Trust – equity proposition

About Edison

About Edison

Careers

SIGA Technologies (NASDAQ: SIGA)

Latest Insights

SIGA Technologies — A solid quarter for topline growth

SIGA Technologies — Another strong period for the order book

SIGA Technologies — Dividends bring cheer amid market uncertainty

SIGA Technologies — Entering a crucial period for business outlook

Sector

Equity Analyst

Key Management

SIGA Technologies — New captain to steer the ship

SIGA Technologies — International momentum building towards year-end

SIGA Technologies — EU gateway to tap into new international orders

SIGA Technologies — Notable CMO appointment to position for growth

SIGA Technologies — Second quarter as expected, onward to H223

SIGA Technologies — US exercised (stockpile) options are key catalysts

SIGA Technologies — Diamond in the rough amid macro weakness

SIGA Technologies — US stockpiles front and center in Q1 and FY23

SIGA Technologies — Solid results marked by revenue diversification

SIGA Technologies — Solid Q322, underpinned by international traction

SIGA Technologies — TPOXX trials launched in treating monkeypox

SIGA Technologies – executive interview

SIGA Technologies — Second contract win from the US DoD in 2022

SIGA Technologies — Monkeypox concern drives international TPOXX win

SIGA Technologies — Monkeypox likely here to stay

SIGA Technologies — BARDA exercises first option for IV TPOXX

SIGA Technologies — Best is yet to come

SIGA Technologies — WHO declares monkeypox a global emergency

SIGA Technologies — The year of international expansion

SIGA Technologies — International expansion for oral TPOXX

SIGA Technologies — IV TPOXX receives FDA Approval

SIGA Technologies — Product and international expansion on track

SIGA Technologies — Geographic expansion underway

SIGA Technologies — Additional approvals expected shortly

SIGA Technologies – executive interview

SIGA Technologies — Q221 results

SIGA Technologies and Cipla Therapeutics – executive interview

SIGA Technologies — Additional international deal possible in Q2

SIGA Technologies – executive interview

SIGA Technologies — Protection against a future pandemic